Vaxart shares are trading higher after the company received a BARDA-funded Project NextGen award valued up to $453 million to conduct a Phase 2b study evaluating its COVID-19 oral pill vaccine candidate.
Portfolio Pulse from Benzinga Newsdesk
Vaxart shares are trading higher after receiving a BARDA-funded Project NextGen award valued up to $453 million to conduct a Phase 2b study for its COVID-19 oral pill vaccine candidate.
June 13, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart shares are trading higher after receiving a BARDA-funded Project NextGen award valued up to $453 million to conduct a Phase 2b study for its COVID-19 oral pill vaccine candidate.
The significant funding from BARDA for the Phase 2b study of Vaxart's COVID-19 oral pill vaccine candidate is a major positive development. This award not only provides substantial financial support but also validates the potential of Vaxart's vaccine technology, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100